Teshaev Oktyabr Ruhullaevich, Ruziyev Umid S
Department of Bariatric Surgery, Tashkent Medical Academy, Tashkent, Uzbekistan.
J Metab Bariatr Surg. 2025 Aug;14(2):150-156. doi: 10.17476/jmbs.2025.14.2.150. Epub 2025 Aug 13.
This study aimed to compare the efficacy and safety of Classic and Hard laparoscopic sleeve gastrectomy (LSG) techniques, with a focus on long-term weight loss outcomes and complication rates over a 3-year follow-up period.
A retrospective cohort study was conducted on 785 patients who underwent LSG between January 2019 and December 2022, with follow-up completed by 2023. Patients were divided into 2 groups according to surgical technique: Classic LSG (n=372), involving standard resection along the lesser curvature using a 36-French bougie; and Hard LSG (n=413), characterized by more extensive fundal mobilization and creation of a narrower gastric tube using a 32-French bougie.
Both techniques resulted in significant body mass index (BMI) reductions; however, Hard LSG demonstrated superior weight loss. At 12 months, 70.7% of Hard LSG patients achieved a normal BMI (<25 kg/m), compared to 42.2% in the Classic group. At 3 years, 59.3% and 20.4% maintained normal BMI, respectively (P<0.001). However, Hard LSG was associated with higher complication rates: early metabolic complications occurred in 64.3% vs. 25.7% (P<0.001), and late surgical complications in 10.4% vs. 2.4% (P<0.001).
While Hard LSG provides greater and more durable weight loss, it is associated with increased risks of complications. These findings support the need for individualized surgical decision-making to balance efficacy and safety in the management of obesity.
本研究旨在比较传统腹腔镜袖状胃切除术(LSG)和改良腹腔镜袖状胃切除术的疗效和安全性,重点关注3年随访期内的长期体重减轻结果和并发症发生率。
对2019年1月至2022年12月期间接受LSG的785例患者进行回顾性队列研究,随访至2023年结束。根据手术技术将患者分为两组:传统LSG组(n = 372),采用36号法式探条沿小弯侧进行标准切除;改良LSG组(n = 413),其特点是更广泛地游离胃底并使用32号法式探条制作更窄的胃管。
两种技术均导致体重指数(BMI)显著降低;然而,改良LSG在体重减轻方面表现更优。在12个月时,改良LSG组70.7%的患者BMI恢复正常(<25 kg/m²),而传统组为42.2%。在3年时,分别有59.3%和20.4%的患者维持正常BMI(P<0.001)。然而,改良LSG的并发症发生率更高:早期代谢并发症发生率分别为64.3%和25.7%(P<0.001),晚期手术并发症发生率分别为10.4%和2.4%(P<0.001)。
虽然改良LSG能实现更大且更持久的体重减轻,但并发症风险增加。这些发现支持在肥胖管理中需要进行个体化手术决策以平衡疗效和安全性。